Categories: News

SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference to be held virtually on Tuesday, September 28, 2021, at 4:00 p.m. ET.

For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to Cantor at corporateaccess@cantor.com or KCSA Strategic Communications at SELLAS@kcsa.com.

About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

For more information, please contact:

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276

Staff

Recent Posts

Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro

Regional program delivers double-digit sales growth, improved service performance, and expanded diagnostic access across Latin…

2 hours ago

GEARWRENCH Continues to Redefine Automotive Diagnostics with Powerful New Tools

Four new products available now to put full diagnostics in the palm of technician's handsSPARKS,…

2 hours ago

Tampa General’s Innovation Week Returns with New Programming to Showcase Breakthroughs in Patient Care and Technology

Global leaders, entrepreneurs and innovators will converge across the Tampa Medical & Research District and…

2 hours ago

New England Biolabs ® Proudly Partners with Automation Providers to Support NGS Library Prep Automation Globally

IPSWICH, Mass., Feb. 6, 2026 /PRNewswire/ -- New England Biolabs (NEB ®) will present several…

2 hours ago

Healthcare Triangle, Inc. Announces 1-for-60 Reverse Stock Split as Part of Nasdaq Compliance Plan

PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"),…

8 hours ago

Rokt Joins American Heart Association’s “Go Red. Shop with Heart” Initiative, Marks Kickoff at NYSE Bell Ringing

NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Rokt, the leading ecommerce technology company using machine learning…

8 hours ago